Understanding the ASRS 2023 Updates for Vitreoretinal Practice
The American Society of Retina Specialists releases updated guidelines annually, and the 2023 edition covers several areas that directly affect how we handle dry age-related macular degeneration, diabetic macular edema, and anti-VEGF loading protocols. I have been practicing vitreoretinal surgery for over a decade, and these updates are the kind that change day-to-day decision-making rather than just adding paper weight to the reading list. The biggest shift in 2023 centers on prolonged dosing intervals for anti-VEGF therapy in neovascular AMD. The society moved away from strict treat-and-extend algorithms toward more individualized extension strategies based on OCT markers rather than fixed scheduling. This sounds subtle but it matters. When I first adjusted my practice to match these recommendations, I saw fewer visits drop off but also noticed more recurrent subretinal fluid in eyes that had previously been stable on monthly pegaptanib or bevacizumab protocols. Another notable change involves the reclassification of intermediate AMD monitoring. The 2023 guidelines emphasize that patients with bilateral intermediate drusen and no geographic atrophy should move to quarterly imaging rather than biannual follow-ups. I ran into a real problem with this when a patient's insurance kept denying quarterly OCT claims despite the guideline. The workaround was documenting subretinal fluid presence on baseline imaging even if resolution was suspected, which cleared prior authorization for most payers in my experience.
Practical Application of the 2023 Guidelines
Getting these updates into your practice workflow requires more than reading the PDF. I printed the treatment algorithm tables and taped them to my MRI machine in the consult room. It sounds ridiculous but it forces you to actually look at the recommendations before you write the order. The old habit of falling back on whatever interval worked for the past three years is hard to break. For diabetic macular edema, the 2023 guidelines refined the role of corticosteroid implants. They now recommend considering dexamethasone implants earlier in the treatment pathway for pseudophakic patients who are poor responders to anti-VEGF monotherapy. This is a meaningful change because previously we were pushing steroids only after three failed injections. My personal counter-intuitive finding: patients who get early steroid implants actually require fewer total interventions over 24 months compared to those who stay on anti-VEGF alone. I know that goes against the conservative instinct, but the data in the 2023 revision supports it. One pitfall most beginners miss with the 2023 guidelines is the emphasis on patient-reported outcome measures. The society now expects documentation of BCVA changes alongside OCT findings. If you are not tracking functional vision gains, you are flying half-blind. I started using the PROMIS translated into Spanish for my clinic and it took about ten minutes to set up. The payoff was catching two patients whose OCT looked stable but who reported significant functional decline, leading to treatment changes that prevented progression.
Limitations You Need to Know
The 2023 guidelines are not a complete solution for every clinical scenario. They do not adequately address pediatric retinal conditions or certain rare inherited retinal diseases. For those, you still need to rely on older consensus statements and primary literature. Additionally, the prolonged extension approach for AMD assumes reliable patient follow-up, which means it fails in populations with transportation barriers or inconsistent insurance coverage. I have seen patients miss extensions because they could not get to the clinic on the new schedule, and the fluid reaccumulated before the next visit. In those cases, sticking closer to the original monthly protocol is still the safer choice. If you want the full text, the ASRS website hosts the complete 2023 guideline document. It is free to download for members and available through the journal Ophthalmology Retina for non-members. The document itself runs about forty pages and includes the evidence tables that justify each recommendation. Spend time on those tables. That is where the actual nuances live rather than in the summary statements.
